BIBLIOGRAPHY


2- Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184


9- D Applebaum-Bowden, P McLean, A Steinmetz, D Fontana, C Matthys, GR Warnick, M Cheung, JJ Albers and WR Hazzard. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women.


19- Hulley, S. et al for the HERS Research Group. (2002). Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and
Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 288: 58-64


28- Michael G. Shlipak, MD, MPH et al; Estrogen and Progestin. Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause JAMA. 2000;283:1845-1852.


37- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The


42- Godsland I F et al, Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein

******